ArticleCureus2025
The Successful Management of Severe Leptospirosis by Using Meropenem and Corticosteroids in the Setting of Multi-Drug Hypersensitivity: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leptospirosis is a globally significant zoonotic infection that poses a major burden on tropical regions. It is often misdiagnosed due to its highly variable clinical spectrum. Although severe leptospirosis is classically characterized by jaundice, acute kidney injury (AKI), and severe pulmonary hemorrhage syndrome (SPHS), atypical anicteric presentations pose diagnostic challenges and delay treatment initiation, increasing mortality risk. We report the case of a 23-year-old female with severe leptospirosis, which presented a significant therapeutic challenge due to hypersensitivity to all first-line antimicrobial agents for leptospirosis, limiting treatment options. Her clinical course was further complicated by the development of SPHS, septic shock, AKI, and severe thrombocytopenia, necessitating critical care support. Interestingly, she had no signs of jaundice or severe hepatic dysfunction. Initial broad-spectrum therapy with piperacillin-tazobactam failed to achieve clinical improvement. Given her worsening clinical condition, antimicrobial therapy was escalated to meropenem alongside methylprednisolone, which led to the progressive resolution of her pulmonary and renal dysfunction within 48 hours. This report highlights the potential efficacy of meropenem as an alternative antimicrobial therapy for leptospirosis when first-line antibiotics are contraindicated, and supports the role of corticosteroids in leptospirosis-associated pulmonary complications. It also underscores the significance of maintaining a high index of clinical suspicion in high-risk populations to facilitate early diagnosis and antibiotic initiation to improve outcomes in atypical presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.